Received Feb 28, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | 3 | DD72H | — |
Product Confusion; This non-serious case was reported by a nurse via call center representative and described the occurrence of product label confusion in a patient who received Men B NVS (Bexsero) (batch number DD72H, expiry date 30-NOV-2027) for prophylaxis. On an unknown date, the patient received the 3rd dose of Bexsero. On an unknown date, an unknown time after receiving Bexsero, the patient experienced product label confusion (Verbatim: Product Confusion). The outcome of the product label confusion was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 12-FEB-2025 The reporter was a nurse from a pediatric office. She reports that they administer Bexsero vaccine. Inappropriate schedule of vaccine, the nurse states they order Bexsero and have been giving it at day one and one month later (as according to the old schedule) due to this an unknown number of patients would now have to receive a third dose. The office staff were unaware of the dosing schedule change because they did not receive a notification. If they had known, they could have advised the patients not to return until the 6 month mark. The nurse was confused as to why the paper copy package insert inside the Bexsero vaccine box (which expires in 2027) would still be showing the original dosing schedule, which led to product label confusion. The vaccine administration facility was the same as primary reporter.